PaxMedica, Common Stock Top Management
PXMDDelisted Stock | USD 0.86 0.18 17.31% |
PaxMedica, Common employs about 6 people. The company is managed by 5 executives with a total tenure of roughly 14 years, averaging almost 2.0 years of service per executive, having 1.2 employees per reported executive. Evaluation of PaxMedica, Common's management performance can provide insight into the firm performance.
Howard Weisman Insider CEO Director |
MS MBA Insider Ex Chairman |
PaxMedica, |
PaxMedica, Common Management Team Effectiveness
The company has return on total asset (ROA) of (2.5596) % which means that it has lost $2.5596 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.4696) %, meaning that it created substantial loss on money invested by shareholders. PaxMedica, Common's management efficiency ratios could be used to measure how well PaxMedica, Common manages its routine affairs as well as how well it operates its assets and liabilities.PaxMedica, Common Workforce Comparison
PaxMedica, Common Stock is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 180. PaxMedica, Common holds roughly 6.0 in number of employees claiming about 3% of equities under Health Care industry.
PaxMedica, Common Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific PaxMedica, Common insiders, such as employees or executives, is commonly permitted as long as it does not rely on PaxMedica, Common's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, PaxMedica, Common insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Larochelle Karen over six months ago Disposition of 604 shares by Larochelle Karen of PaxMedica Common at 0.69 subject to Rule 16b-3 | ||
Casamento Charles J over six months ago Disposition of 992 shares by Casamento Charles J of PaxMedica Common at 0.69 subject to Rule 16b-3 | ||
Hough David W over six months ago Payment of 291 shares by Hough David W of PaxMedica Common subject to Rule 16b-3 | ||
Stephen Sheldon over six months ago Disposition of 243 shares by Stephen Sheldon of PaxMedica Common at 0.659 subject to Rule 16b-3 | ||
Coelho John F over six months ago Sale by Coelho John F of tradable shares of PaxMedica Common | ||
Coelho John F over six months ago Sale by Coelho John F of tradable shares of PaxMedica Common | ||
Stephen Sheldon over a year ago Payment of 971 shares by Stephen Sheldon of PaxMedica Common subject to Rule 16b-3 | ||
Coelho John F over a year ago Sale by Coelho John F of 570 shares of PaxMedica Common |
PaxMedica, Common Notable Stakeholders
A PaxMedica, Common stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as PaxMedica, Common often face trade-offs trying to please all of them. PaxMedica, Common's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting PaxMedica, Common's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Howard Weisman | CEO Director | Profile | |
MS MBA | Ex Chairman | Profile | |
Zachary Rome | COO Director | Profile | |
Stephen Sheldon | Chief Officer | Profile | |
David MD | Chief Officer | Profile |
About PaxMedica, Common Management Performance
The success or failure of an entity such as PaxMedica, Common Stock often depends on how effective the management is. PaxMedica, Common management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of PaxMedica, management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the PaxMedica, management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC. Paxmedica operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2 people.
Please note, the presentation of PaxMedica, Common's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, PaxMedica, Common's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of PaxMedica, Common's management manipulating its earnings.
PaxMedica, Common Workforce Analysis
Traditionally, organizations such as PaxMedica, Common use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare PaxMedica, Common within its industry.PaxMedica, Common Manpower Efficiency
Return on PaxMedica, Common Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 3M | |
Net Loss Per Executive | 3.7M | |
Working Capital Per Employee | 647.5K | |
Working Capital Per Executive | 777K |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in PaxMedica, Pink Sheet
If you are still planning to invest in PaxMedica, Common Stock check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PaxMedica, Common's history and understand the potential risks before investing.
Commodity Directory Find actively traded commodities issued by global exchanges | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |